Amarin Corp Plcuk (AMRN) Non-Current Debt (2010 - 2020)
Amarin Corp Plc\Uk (AMRN) posted quarterly Non-Current Debt of $9.4 million for Q3 2020, up 5.73% year-over-year from $8.9 million in Q4 2019, and down 57.84% quarter-over-quarter from $22.3 million in Q2 2020.
Amarin Corp Plcuk (AMRN) Non-Current Debt (2010 - 2020) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Non-Current Debt for 11 consecutive years, with $9.4 million the latest figure, recorded in Q3 2020.
- In Q3 2020, Non-Current Debt rose 5.73% year-over-year to $9.4 million; the TTM figure through Sep 2020 stood at $9.4 million (up 5.73% YoY), while the FY2019 annual figure was $49.7 million, up 7.79% from the prior year.
- Non-Current Debt slipped to $9.4 million in Q3 2020 per AMRN's latest filing, from $22.3 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $138.7 million in Q1 2016 and bottomed at $8.9 million in Q3 2019.
- Historically, Non-Current Debt has averaged $59.3 million across 5 years, with a median of $56.7 million in 2018.
- Annual changes were most pronounced in 2016 — Non-Current Debt grew 12.59% — and 2019, when it slumped 83.54%.
- Amarin Corp Plc\Uk's Non-Current Debt stood at $85.2 million in 2016, then slipped by 16.82% to $70.8 million in 2017, then plunged by 34.91% to $46.1 million in 2018, then advanced by 7.79% to $49.7 million in 2019, then slumped by 81.11% to $9.4 million in 2020.
- Business Quant data shows AMRN's Non-Current Debt at $9.4 million in Q3 2020, $22.3 million in Q2 2020, and $36.7 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.81 Bn | 632.06 Bn | 17.26 Bn | 37.34 Bn |
| 2 | AbbVie | 470.36 Bn | 463.79 Bn | 12.70 Bn | 62.48 Bn |
| 3 | Merck | 375.71 Bn | 368.57 Bn | 12.21 Bn | 51.08 Bn |
| 4 | Novartis Ag | 303.50 Bn | 295.81 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.38 Bn | 252.48 Bn | 12.86 Bn | 23.68 Bn |
| 6 | Amgen | 236.44 Bn | 222.45 Bn | 7.24 Bn | 57.30 Bn |
| 7 | Gilead Sciences | 181.93 Bn | 178.75 Bn | 6.22 Bn | 26.25 Bn |
| 8 | Pfizer | 159.38 Bn | 147.68 Bn | 10.94 Bn | 60.50 Bn |
| 9 | Gsk | 106.17 Bn | 102.00 Bn | 8.24 Bn | -18.71 Bn |
| 10 | Amarin Corp Plcuk | 5.87 Bn | 5.56 Bn | 14.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 9.39 Mn |
| Jun 30, 2020 | 22.27 Mn |
| Mar 31, 2020 | 36.66 Mn |
| Dec 31, 2019 | 49.70 Mn |
| Sep 30, 2019 | 8.88 Mn |
| Jun 30, 2019 | 23.20 Mn |
| Mar 31, 2019 | 35.34 Mn |
| Dec 31, 2018 | 46.11 Mn |
| Sep 30, 2018 | 53.92 Mn |
| Jun 30, 2018 | 59.56 Mn |
| Mar 31, 2018 | 65.48 Mn |
| Dec 31, 2017 | 70.83 Mn |
| Sep 30, 2017 | 75.56 Mn |
| Jun 30, 2017 | 79.28 Mn |
| Mar 31, 2017 | 82.41 Mn |
| Dec 31, 2016 | 85.16 Mn |
| Jun 30, 2016 | 125.64 Mn |
| Mar 31, 2016 | 138.70 Mn |
| Dec 31, 2015 | 136.73 Mn |
| Sep 30, 2015 | 126.11 Mn |